

Innovative COVID-19 Point-of-Care Diagnostics Suitable for Tuberculosis Diagnosis: A Scoping Review

Lydia Holtgrewe^{1*}, Sonal Jain¹, Ralitza Dekova¹, Tobias Broger¹, Chris Isaacs², Payam Nahid³, Adithya Cattamanchi^{3,4}, Claudia M. Denking^{1,5}, Seda Yerlikaya¹

¹Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, Heidelberg, Germany.

²Connected Diagnostics Limited, London, UK.

³UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.

⁴Division of Pulmonary Diseases and Critical Medicine, University of California Irvine, Irvine, California, USA.

⁵German Center for Infection Research (DZIF), Partner Site Heidelberg University Hospital, Heidelberg, Germany

* Corresponding author: lmlh1g18@soton.ac.uk

ORCID numbers:

- Lydia Holtgrewe: 0000-0003-3692-0469
- Sonal Jain: 0000-0003-3252-1727
- Ralitza Dekova: 0000-0002-3519-1164
- Tobias Broger: 0000-0002-7959-1055
- Chris Isaacs: 0009-0001-3443-358X
- Payam Nahid: 0000-0003-2811-1311
- Adithya Cattamanchi: 0000-0002-6553-2601
- Claudia Denking: 0000-0002-7216-7067
- Seda Yerlikaya: 0000-0002-6064-548X

Abstract

Introduction

Rapid and accurate point-of-care (POC) tuberculosis (TB) diagnostics are a key priority to close the TB diagnostic gap of 3.1 million people without a diagnosis. Leveraging the recent surge in COVID-19 diagnostic innovation, we explored the potential adaptation of commercially available SARS-CoV-2 tests for TB diagnosis, aligning with World Health Organization (WHO) target product profiles (TPPs).

Methods

A scoping review was conducted following PRISMA-ScR guidelines to systematically map commercially available POC molecular and antigen SARS-CoV-2 diagnostic tests potentially meeting the TPPs for TB diagnostic tests for peripheral settings. Data were gathered from PubMed/MEDLINE, bioRxiv, and medRxiv, along with publicly accessible *in vitro* diagnostic test databases, and developer websites, up to November 23, 2022. Data on developer and test attributes, operational characteristics, pricing, and clinical performance were charted using standardized data extraction forms. Each identified test was evaluated using a standardized scorecard. A narrative synthesis of the charted data is presented.

Results

Our database search yielded 2,003 studies, from which 408 were considered eligible. Among these, we identified 58 commercialized diagnostic devices, including 17 near-POC antigen tests, one POC molecular test, 29 near-POC molecular tests, and 11 low-complexity molecular tests. We summarized the detailed characteristics, regulatory status, and clinical performance data of these tests. The *LumiraDx* (Roche, Switzerland) emerged as the highest-scoring near-POC antigen platform, while *Visby* (Visby, USA) was the highest-performing near-POC molecular platform. The *Lucira Check-It* (Pfizer, USA) was noted as the sole POC molecular test. The *IdyllaTM* (Biocartis, Switzerland) was identified as the leading low-complexity molecular test.

Discussion

We highlight a diverse landscape of commercially available diagnostic tests suitable for potential adaptation to TB POC testing. This work aims to bolster global TB initiatives by fostering stakeholder collaboration, leveraging COVID-19 diagnostic technologies for TB diagnosis, and uncovering new commercial avenues to tackle longstanding challenges in TB diagnosis.

KEYWORDS

Tuberculosis; COVID-19; SARS-CoV-2; Rapid Diagnostic Tests; Point-of-Care Testing; Missed Diagnosis

1 INTRODUCTION

1.1 RATIONALE

While healthcare systems are slowly recovering from the disruptive impacts of the COVID-19 pandemic, tuberculosis (TB) remains the world's leading infectious killer. It accounted for 1.6 million new cases and 1.3 million deaths in 2022 alone^[1]. Despite a modest 8.7% reduction in TB incidence between 2015 and 2022, the global community remains far away from achieving the 50% reduction target set by the World Health Organization (WHO) End TB Strategy for 2025^[1]. To reach this milestone and to curb the community transmission of TB, effective diagnosis and treatment of people with TB is essential^[2]. Closing the many gaps in the TB care cascade necessitates improvements in access to TB testing, optimized utilization of diagnostic tests, and strengthening the linkage to TB treatment^[3]. Bridging the diagnostic gap requires rapid, accurate, and affordable diagnostic tests suitable for use at point-of-care (POC).

In an effort to guide developers towards fit-for-purpose TB diagnostics, the WHO defined high priority target product profiles (TPP) in 2014^[4]. Currently, a revision of these TPPs is underway, with a preliminary draft having been shared in August 2023 as part of a public consultation^[5]. Current WHO-recommended rapid diagnostic tests (WRDs) fall short of the minimal TPP requirements for a TB diagnostic for peripheral settings, either due to a reliance on sputum specimens, inadequate clinical performance, cost, and/or limited operational suitability^[4, 6, 7]. As a result, as of 2022, only 47% of notified TB cases worldwide were diagnosed using WRDs^[8-10]. Fit-for-purpose POC TB diagnostic tests that meet TPP criteria are needed to achieve the WHO's goal of attaining 100% global coverage of WRDs^[10].

Leveraging the rapid advances in diagnostic technology as a result of the COVID-19 pandemic offers the potential to rapidly develop better solutions for TB diagnosis. Through increased funding and collaborative initiatives, such as the Access to COVID-19 Tools (ACT) Accelerator or RADx, the pandemic created growth opportunities for key market players and fueled an unprecedented momentum in the research and development (R&D) of novel diagnostics^[11]. This resulted in the development of a diverse array of diagnostic products for remote and at-home testing^[12]. As the size of the global COVID-19 diagnostics market is declining^[11], developers are looking for new avenues to apply their innovations. TB can emerge as a practical choice for these developers given the substantial disease burden, supportive government initiatives, and in-kind funding to support validation through established research networks.

1.2 OBJECTIVES

This scoping review was conducted to systematically map the commercially available molecular and antigen SARS-CoV-2 diagnostic tests with the potential of meeting the 2014 TPP for new POC TB diagnostics^[4]. This compilation of commercialized diagnostic tools seeks to identify promising innovations to facilitate interactions between device and assay

developers with other key stakeholders, leveraging the momentum in diagnostic innovation spurred by COVID-19 to address gaps in TB diagnostics.

2 METHODS

This is a scoping review of the scientific literature, SARS-CoV-2 test databases, and information made available by developers. It follows the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines (see *Table S1*), and the methodological framework developed by *Levac et al*^[13, 14].

2.1 PROTOCOL AND REGISTRATION

We previously published the protocol for this scoping review^[15]. Because of the vast amount of identified literature, we split the work into two, with this publication focusing exclusively on commercialized diagnostics and a publication (in preparation) pertaining to the tests that are either in the pre-commercialization stage or are still in development.

2.2 DEFINITIONS AND ELIGIBILITY CRITERIA

The definitions and eligibility criteria for diagnostic devices used in this work are defined in the protocol^[15]. We added the following sub-categories for peripheral *in vitro* diagnostic (IVD) tests:

- **POC tests:** Diagnostic tests performed at or near the site of patient care. These tests are designed to be instrument-free, disposable, and do not require specific infrastructure, such as access to mains electricity, laboratory equipment, or a cold chain. They can be placed in healthcare settings without laboratory infrastructure and do not require any special skills to administered. Example: *Alere Determine TB LAM Ag Test* (Abbott, IL, USA).
- **Near-POC tests:** Diagnostics tests that are instrument-based and only require basic infrastructure, such as mains electricity for recharging batteries or operating instruments. These test can be used in healthcare settings without laboratories and can be performed by healthcare workers with basic technical skills, such as simple pipetting and sample transfer that do not require precise timing or volumes. Ideally, these tests come with transfer pipettes with pre-set volumes provided by the manufacturer to avoid the need for laboratory skills. Example: *GeneXpert Edge* (Cepheid, CA, USA).
- **Low-complexity tests:** Instrument-based tests intended for use in healthcare settings with basic laboratory infrastructure and access to mains electricity. These tests require basic technical skills and laboratory equipment, including pipettes, vortex mixers, heating devices, freezers, and separate test tubes. Examples: *Truenat* (Molbio Diagnostics, India), *GeneXpert 6-/10-color platforms* (Cepheid, CA, USA).

We made the following modification to the eligibility criteria of POC molecular and antigen tests used for SARS-CoV-2 detection in the scoping review protocol^[15]:

- Minimal biosafety requirements (e.g., personal protective equipment (PPE), good ventilation, and a biohazard bag for waste disposal): because only very few devices reported data on this parameter, we decided to omit it from the data collection.

2.3 INFORMATION SOURCES

As specified in the protocol, we initially searched for relevant peer-reviewed literature in PubMed/MEDLINE and for pre-prints in bioRxiv and medRxiv^[15]. We then searched additional IVD databases and developer websites to obtain supplementary information on each diagnostic test identified through the above-mentioned databases. We updated the website links to the following IVD databases:

- U.S. Food and Drug Administration (FDA) Tables of *In Vitro* Diagnostics Emergency Use Authorizations: <https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2>.
- National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®): <https://www.nibib.nih.gov/covid-19/radx-tech-program/authorized-tests>.

The NMPA - China Medical Products Administration Database

(<https://www.nmpa.gov.cn/datasearch/en/search-result-en.html?nmpaItem=82808081889a0b5601889a251e33005c>) and CDSCO - Government of India, Central Drugs

Standard Control Organization (<https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/InVitro-Diagnostics/>) had limited search function and language barriers and the majority of devices could not be identified. The EUDAMED

(<https://ec.europa.eu/tools/eudamed/#/screen/search-device>) was not accessible for data

search at the time of data collection.^[16]

2.4 SEARCH STRATEGY

The full search term for PubMed/MEDLINE is shown in *Table 1* in the protocol^[15]. It was adapted as necessary for the other databases bioRxiv and medRxiv using the medrxivr package in R (version 4.0.5; R Foundation for Statistical Computing) to overcome the limitations of the search functionality of these websites and allow for reproducibility. The analytical R code can be found in the *Supplementary Methods, Section 1*. We did not impose any restrictions on the publication date or language of relevant manuscripts.

2.5 SELECTION OF SOURCES OF EVIDENCE

Retrieved articles were collated using Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia; available at www.covidence.com) and duplicates were automatically removed^[17]. The same software was used for screening. Two reviewers (S.Y., L.H.) independently screened titles and abstracts against the eligibility criteria. Then, full-text screening was performed by the same reviewers. Any discrepancies were resolved through consensus.

2.6 DATA CHARTING PROCESS

We used two Google forms for data charting. The forms were developed by one reviewer (S.Y.) and revised in an iterative process by both reviewers (S.Y., L.H.) during initial data charting. One reviewer (L.H.) charted information on study design, test characteristics, and clinical performance from eligible studies using the first standardized form (see *Table S2*). For studies that mentioned more than one test, multiple records were charted (one record per test). The same reviewer (L.H.) used the second standardized form to collect additional information on tests identified during the first charting step, drawing on additional sources, such as the developer's website, and the regulatory databases listed above (see *Table S3*). Due to a high number of extracted publications, only the results tables, and not the primary data, were cross-checked by a second reviewer (S.J. and R.D.). Data charted from various sources were collated on separate excel sheets for each diagnostic test.

2.7 VARIABLES

We abstracted data on test description, operation characteristics, pricing, performance, and commercialization status, as listed in *Table 2* in the study protocol^[15]. Variables are defined in the data charting forms.

2.8 SYNTHESIS OF RESULTS

In accordance with current standards for scoping reviews and evidence mapping, a narrative synthesis of information is provided in the text and tables to summarize and explain major aspects of the included diagnostic tests, such as information on the developer, test characteristics, and clinical performance data stratified by technology type (antigen and molecular) and test classification (low-complexity, near-POC, and POC).

We modified *Lehe et al.*'s standardized scorecard, created for the objective evaluation of operational characteristics of POC diagnostic devices, to align with the diagnostic requirements of the WHO's TPP in order to reduce subjectivity in the assessment of the included SARS-CoV-2 diagnostic devices^[18]. Diagnostic devices received an overall score of a minimum of zero to a maximum of 110 points based on 22 scoring criteria. Scoring criteria were classified into seven scoring categories. Each scoring criterion was assigned one to five points, with one being the lowest, and five being the highest possible score. When information was missing, the lowest score of one point was given. The adapted scoring framework, including definitions of all scoring criteria, is shown in the *Table S4*. Each diagnostic device was independently scored by two reviewers (L.H., S.J.) and scoring conflicts were resolved through consensus and discussion with a third reviewer (S.Y.). We present device characteristics and performance of the highest-scoring diagnostic tests in each of the six categories in tables, figures, and text.

3 RESULTS

3.1 SELECTION OF SOURCES OF EVIDENCE

Database search yielded 2,003 results that were imported into Covidence for screening. After 248 duplicates were automatically removed by Covidence, 1754 studies underwent title/abstract screening, out of which 874 were considered eligible for full-text screening. Among these, the most common reasons for exclusion were inclusion of assays and instruments that were ineligible for use in peripheral settings ($n = 234$), no mention of specific tests ($n = 127$) and reporting on conventional lateral flow assays without reading devices or enhanced detection technologies ($n = 56$), as shown in Fig. 1. From the 408 studies considered eligible for inclusion in this review, 58 commercialized diagnostic devices were identified using the primary sources of evidence.




Fig. 1. PRISMA Flow Chart, showing the results of study search and screening procedures.

Abbreviations: PoC = Point-Of-Care; LFT = Lateral Flow Test; PCR = Polymerase Chain Reaction.

Legend: *For studies that mentioned more than one tests, multiple records were charted (one record

per test).

3.2 CHARACTERISTICS OF INDIVIDUAL SOURCES OF EVIDENCE

The data charted from included evidence sources is described in *Table 1*, along with comments on the source characteristics.

Table 1. Characteristics of included sources of evidence and charted data variables.

Source of evidence and article type	Charted data variables	Comments
Primary sources of evidence	Analytical research paper	• Focus on the development of new diagnostic tools, with predominantly proof-of-concept studies and early development of platforms for diagnostic assays; • Early-stage, pilot performance studies in a small number of participants; • Price estimates were rarely provided • Seldom contained data on commercialized diagnostic devices, focus on products in the early stages of development
	Clinical research paper	• (Pooled) test performance of commercialized diagnostic tests, comparing performance of the diagnostic test under investigation against the gold-standard for SARS-CoV-2 diagnosis, RT-PCR. • Source of study-reported performance data
	Systematic review	• Range of or pooled test performance; • Little further information on developer or diagnostic test • Source of range of pooled performance data
	Narrative review	• Description of a range of diagnostic tests falling within the scope of the review topic, including technical details of the diagnostic test and operational characteristics; • Clinical performance (mostly developer-reported); • Pricing was rarely mentioned • Performance data was often extracted from the developer's website
Secondary sources of evidence	Developer website	• Supplementary data on diagnostic assays and instruments, in particular information on technical details, workflow, costs, and end user requirements; • Developer-reported performance data • Discrepancies between developer-reported and study-reported performance data
	Regulatory agencies	• Identification of instructions for use (IFU) documentation, which provided complementary information on assays and diagnostic device characteristics; • Regulatory status in the respective countries • Main source for standardized, complete information on diagnostics approved tests
	SARS-CoV-2 test databases: FIND COVID-19 Test Directory, Johns Hopkins COVID-19 Testing Toolkit,	• Overview of regulatory status globally, performance data, validated sample types and target analyte • Main source used to obtain information on the regulatory status of diagnostic devices globally, and to link products to country-specific databases

and NIH RADx[†]

Abbreviations: RT-PCR = Reverse-Transcriptase Polymerase Chain reaction; IFU = Instructions For Use; NIH RADx = National Institutes of Health Rapid Acceleration of Diagnostics.

Legend: *FIND COVID-19 Test Directory: <https://www.finddx.org/tools-and-resources/dxconnect/test-directories/covid-19-test-directory/>; Johns Hopkins COVID-19 Testing Toolkit: <https://covid19testingtoolkit.centerforhealthsecurity.org/testing-trackers/antigen-and-molecular-tests-for-covid-19>; NIH RADx: <https://www.nibib.nih.gov/covid-19/radx-tech-program/authorized-tests>.

3.3 SYNTHESIS OF RESULTS

Out of 58 commercialized POC diagnostic tests for SARS-CoV-2, we identified 17 near-POC antigen tests, one POC molecular test, 29 near-POC molecular tests, and 11 low-complexity molecular tests. By definition, there were no POC antigen tests in the review because we excluded conventional instrument-free LFTs. The 55 manufacturers of included diagnostic tests are displayed in Fig. 2. Developer and product characteristics, regulatory status, and clinical performance data of all included diagnostic tests are shown in Table S5-S8. Table 2 displays platform and assay characteristics, clinical performance, and end-user requirements of the single highest-scoring diagnostic test within each diagnostic category. For each of the three highest-scoring diagnostic tests within each diagnostic category, Fig. 3 shows the scores across all seven categories.

3.3.1 Near-POC Antigen Tests

We identified 17 tests that met the eligibility criteria. Six of those were reader-based LFTs, whereas 11 were automated immunoassays. Even though the *Covid-19 Home Test* (Ellume Health, Australia) is an LFT, we included it in this category since result interpretation requires a mobile phone. Table 2 summarizes the characteristics of the highest-scoring near-POC antigen test, the *LumiraDx* (LumiraDx, UK, recently acquired by Roche Diagnostics, Switzerland)^[19], a multi-use, microfluidic immunofluorescence assay intended for the qualitative detection of antigens in non-sputum nasal swab (NS) and nasopharyngeal samples (NPS).

3.3.2 POC Molecular Tests

We identified one true POC molecular test that requires two AA batteries to operate and is disposable: *Lucira Check It COVID-19 Test* (Pfizer, NY, USA). It can be used for the qualitative detection of RNA in nasal swab (NS) samples.

3.3.2 Near-POC Molecular Tests

All 29 near-POC molecular tests included in the review were based on either PCR (n = 25 tests) or isothermal amplification (n = 5 tests). The vast majority of these tests are tabletop platforms, although we identified some smaller, handheld platforms like *Cue Reader* (Cue, CA, USA), *DoctorVida Pocket Test* (STAB Vida, Portugal) and *Accula Dock* (Thermo Fisher Scientific, MA, USA). We identified one disposable molecular test: *Visby COVID-19 Test*

(Visby, CA, USA). Even though the test is disposable, because it requires stable power, we included it in this category.

3.3.3 Low-Complexity Molecular Tests

As with the already mentioned molecular tests, the low-complexity molecular tests we identified were also based on either PCR (n = 7 tests) or isothermal amplification technology (n = 4 tests). The highest-scoring in this diagnostic category was *Idylla*TM (Biocartis, Switzerland), a multi-use tabletop platform, weighing 18kg and running on standard electricity that is designed for the detection of RNA in NPS.

Near-POC Antigen



Canon

POC Molecular



Low-complexity Molecular



Near-POC Molecular



Fig.2. Logo chart, displaying the 55 manufacturers of all 58 included diagnostic tests.

Abbreviations: PoC = Point-Of-Care.

Table 2. Characteristics of highest-scoring diagnostic devices stratified by test category.

Diagnostic category			Antigen Tests	Molecular Tests		
TPP classification			Near-POC	POC	Near-POC	Low-complexity
Developer, product name			LumiraDx, LumiraDx	Pfizer, Lucira Health	Visby, COVID-19 Test	Biocartis, Idylla™
Overall score			73/110 (66%)*	83/110 (75%)	78/110 (71%)	66/110 (60%)
Test summary	Platform: Specifications	Dimensions (cm)	21 x 9.7 x 7.3	19.1 x 8.0 x 5.2	13.8 x 6.7 x 4.4	30.5 x 19 x 50.5
		Weight (g)	1,100	150	NR	18,600
		Power-supply	Integrated battery (20 tests)	AA batteries	Standard electricity (power adapter)	Standard electricity
		Connectivity	LumiraDx Connect cloud-based services; 2x USB ports; RFID reader; Bluetooth connectivity	None	None	USB port; Direct RJ45 Ethernet cable; Idylla Visualizer (PDF viewer); Idylla Explore (cloud)
		Max. operating temperature (°C)/humidity (%)	30 / 90	45 / 95	30 / 80	30 / 80
		Multi-use [†]	Yes	Yes	Yes	Yes
		Throughput capacity	1	1	1	8
		Costs (USD)	NR	Not applicable (instrument-free)	Not applicable (instrument-free)	NR
	COVID-19 Assay: Specifications	Sample type	NS, NPS	NS	NS, NPS	NPS
		Hands-on time (min)	1	1	<2	<2
		Running time (min)	12	30	30	90
		Shelf-life (months)	NR	18	NR	NR
		Costs per test (USD)	NR	> 10/test	NR	NR
		LOD (copies/mL)	NR	900	100 - 1112	500
		Sensitivity (%) / Specificity (%)	82.7 / 96.9	93.1 / 100.0	100.0 / 98.7	100.0 / 100.0
POC features	Score		39/50 (78%)	36/50 (72%)	36/50 (72%)	32/50 (64%)

of equipment	Pros	• Compact instrument size and weight • Short test preparation and running time • Battery-powered (20 tests per charge cycle) • Fully integrated platform with cloud and EHR connectivity • Fully integrated data analysis	• Compact instrument size and weight • Short test preparation and running time • Battery-powered • Instrument-free, fully integrated platform • Fully integrated data analysis	• Compact instrument size and weight • Short test preparation and running time • Instrument-free, fully integrated platform • Fully integrated data analysis	• High throughput capacity (n=8) • Fully integrated platform with multiple options for data export and connectivity • Fully integrated data analysis • Short test preparation time
	Cons	• Low throughput capacity for an instrument-based assay (n=1)	• No connectivity	• No connectivity • Uninterrupted power supply required	• Large instrument size and heavy weight • Uninterrupted power supply required
POC features of consumables	Score	9/15 (60%)	14/15 (93%)	7/15 (47%)	7/15 (47%)
	Pros	• High operating humidity	• High operating temperature and humidity • Long shelf-life		
	Cons	• Unknown shelf-life		• Unknown shelf-life • Low operating temperature	• Unknown shelf-life • Low operating temperature
Ease of use	Score	10/10 (100%)	10/10 (100%)	8/10 (80%)	6/10 (60%)
	Pros	• Can be used by community or lay worker without technical skills • No manual sample processing steps	• Can be used by community or lay worker without technical skills, suitable for self-testing • No manual sample processing steps	• Can be used by community or lay worker without technical skills, suitable for self-testing • Minimal sample processing steps	• Can be used by healthcare workers with a minimum of training
	Cons				• Sample processing steps require laboratory equipment (pipettes, vortex)
Performance	Score	5/15 (33%)	7/15 (47%)	11/15 (73%)	11/15 (73%)
	Pros	• Discrepancy between developer-reported and study-reported sensitivity data	• High study-reported specificity	• High study-reported sensitivity and specificity	• High clinical sensitivity and specificity
	Cons	• No LoD reported • Poor study-reported sensitivity	• High LoD • Low study-reported sensitivity	• High LoD	• High LoD
Cost	Score	2/10 (20%)	6/10 (60%)	6/10 (60%)	2/10 (20%)
	Pros		• No instrument costs	• No instrument costs	
	Cons	• Costs not transparently reported	• High consumable costs	• Consumable costs not transparently reported	• Costs not transparently reported


Applicability of platform to the TB market	Score	5/5 (100%)	5/5 (100%)	5/5 (100%)	5/5 (100%)
	Pros	• Multi-use platform	• Multi-use platform	• Multi-use platform	• Multi-use platform
	Cons				

Abbreviations: PoC = Point-Of-Care; NR = Not Reported; NS = Nasal Swab; NPS = Nasopharyngeal Sample; LoD = Limit-Of-Detection.


Legend: *Color coding: red = overall score/category score <33.3%; orange = overall score/category score <66.6%; green = overall score/category score >=66.6%.

[†]Multi-use is defined as the ability to run diagnostic assays for different indications on the diagnostic device (e.g., respiratory panels).


A. Near-POC Antigen Tests



B. POC Molecular Tests



C. Near-POC Molecular Tests



D. Low-complexity Molecular Tests




Fig 3. Performance of the three highest-scoring diagnostic devices across the seven scoring categories.

Abbreviations: PoC = Point-Of-Care.

Legend: *Costs (including capital costs and consumable costs) were not reported for most diagnostic tests, resulting in a score of 1/5 (20%).

4 DISCUSSION

In this comprehensive scoping review, we identified 58 commercially available molecular and antigen tests for the diagnosis of SARS-CoV-2 at POC and assessed their applicability to TB. Our findings reveal a diverse array of diagnostic tests and instruments that hold potential in meeting the requirements of peripheral TB diagnostic testing.

NEAR-POC ANTIGEN TESTS

The identified instrument-based near-POC antigen tests offer potential for meeting TPP sensitivity targets for TB antigen detection by employing signal-amplifying technologies, like readers paired with lateral flow assays and automated immunoassays utilizing sensitive detection methods, including fluorescence and electrochemical approaches. The front-runner, the *LumiraDx*, shows promising clinical performance with a low LoD of 2-56 PFU/mL in direct comparison with other tests^[20]. However, reported diagnostic sensitivity of COVID-19 assays included in the review varied widely, ranging from 37.5% to 90.0%, with limited data on LoD. This complicates the assessment of their potential to detect low-abundance TB antigens like lipoarabinomannan (LAM) in urine, where an LoD in the low pg/mL range is likely required so that the test can be used to detect TB in all patient groups^[21]. To enable meaningful comparisons between assays, standardized LoD reporting is required^[22]. Moreover, none of the identified platforms reported to use urine samples^[23, 24]. As a result, successful application of identified platforms to TB will depend on optimized sample pre-treatment and concentration methods, specific anti-LAM antibodies, and sensitive readout approaches.

Overall, identified antigen tests excel in compact design, portability, and rapid turnaround-times, suited for decentralized settings. The *LumiraDx* is notable for its quick turnaround time, battery-operation, and multiple data export options, reducing reliance on Wi-Fi, though it only operates within limited temperature ranges^[25]. Designing TB diagnostics must consider high temperatures and humidity in TB-endemic countries. Many identified tests also support multi-disease testing, challenging siloed testing programs, and facilitating differential diagnosis^[26].

POC AND NEAR-POC MOLECULAR TESTS

POC and near-POC molecular tests highlighted in this review present a variety of innovative assay technologies and platform features. These are designed to enhance user friendliness and testing capacity, incorporating features such as easy handling, self-testing options, rapid turnaround times, and the ability to detect multiple pathogens using multi-disease panels. The surge of new diagnostic tests has significantly boosted the scale up of SARS-CoV-2 diagnostic testing. However, adapting these molecular platforms for TB detection presents technical challenges due to *Mycobacterium tuberculosis* (*Mtb*)'s complex cell wall and low bacterial loads in clinical samples^[6]. Firstly, obtaining non-sputum samples like tongue swabs, breath aerosols (XBA), and stool samples with high bacterial loads requires optimized

collection to maximize bacterial capture^[6, 27, 28]. Recent research suggests almost equal sensitivity of tongue swab PCR compared to sputum in symptomatic patients with “low” or higher sputum bacillary loads^[29]. More research is needed for “very low” and “trace” sputum bacillary load cases. Most identified near-POC molecular tests support oral swabs, indicating adaptability to TB. Further, advances in aerosol collection using POC face masks in combination with cartridge-based NAATs make XBA a promising specimen, but sample processing needs streamlining^[30, 31]. Additionally, stool samples’ acceptable sensitivity in children and simplified processing methods could enhance POC feasibility^[32-34]. Despite being less sensitive than sputum samples, these less-invasive methods paired with molecular platforms suitable for use at POC could enhance diagnostic yield and patient acceptability and reduce overprescribing of empiric antibiotics^[35, 36].

Secondly, while most identified molecular tests employ enzymatic or chemical lysis to release SARS-CoV-2 nucleic acids, mechanical lysis methods, like bead beating or sonication to break down *Mtb*’s lipid-rich cell wall are likely to be required ^[6]. Integration of these methods into a POC platform can be challenging. Alternatively, an accompanying POC device for mechanical lysis from swab samples could be envisioned, provided that the ease-of-use of the overall sample-to-result workflow is sustained ^[37, 38]. With tongue swabs, nucleic acid extraction may be skipped if cell lysis is efficient, simplifying the workflow^[29].

Lastly, high-yield sample lysis must pair with sensitive molecular detection methods. For instance, the frontrunner candidate, *Lucira Check It* uses RT-LAMP, while *Visby COVID-19 Test* employs RT-PCR. Currently available isothermal amplification-based TB assays show high sensitivity but are limited in peripheral settings due to manual processes and outsourced DNA lysis and extraction^[39, 40]. Integrating these assays with sensitive POC platforms, as identified here, could streamline testing.

Operational limitations of molecular platforms identified in this review may hinder their widespread adoption in peripheral settings. Some, like *Visby COVID-19 Test* and *Accula Dock* require a standard power source, affecting implementation in areas with unstable power supply^[41]. *Lucira Check It* and *Cue Reader* address this with AA batteries or smartphone battery charge, but reliance on smartphones may still pose limitations. Further, most tests, including *Lucira Check It* and *Visby COVID-19 Test*, lack adequate data export options to reduce reliance on Wi-Fi connectivity. This raises concerns about manual result documentation, increasing the risk of human error and data loss, and hindering communities’ ability to fully leverage generated data^[41-43]. Adapting to the needs of areas with limited internet and electronic medical record systems is essential to overcome these challenges^[42]. Finally, many promising near-POC platforms have low daily sample throughput and limited multi-use capacity, hindering parallel sample analysis and potentially causing treatment delays. Among these platforms, *Franklin™* (Biomeme, PA, US) stands out, offering the detection of up to 27 targets in 9 samples per PCR run, including sexually transmitted-, mosquito-borne-, and respiratory pathogens. Multi-disease panels are crucial for integrated public health interventions and should be prioritized in the

development of novel diagnostics^[44]. Co-testing for TB, HIV, diabetes, and respiratory pathogens, in particular, could significantly benefit national health programs, guided by the WHO's essential diagnostics list^[45].

The at-home molecular tests suitable for self-testing, such as *Visby COVID-19 Test*, *Lucira Check It*, and *Cue Reader* show significant promise to meet TPP criteria. Their palm-sized format, minimal sample pre-processing, rapid result delivery, and minimal user training render them ideal for decentralized settings. To fully realize their potential, temperature and humidity ranges should be considered in TB-endemic settings, similar to the identified antigen tests. The recent shutdown of Cue Health highlights the importance of expanding COVID-19 test platforms to other disease areas, such as TB, to capitalize on the rapidly growing TB diagnostic market^[46].

LOW-COMPLEXITY MOLECULAR TESTS

The *GENIE® II* (Optigene, UK), ranked second among the low-complexity platforms, holds potential to bridge gaps left by current WHO-recommended molecular systems^[47]. It is battery-powered, operates at high temperatures (40 °C), has a rapid 30-minute turnaround time for 16 samples, and accommodates USB data export. Additional LAMP primers can be designed to expand the diagnostic panel^[48]. However, the instrument necessitates additional equipment for sample pre-treatment, limiting peripheral deployment, though simplifying sample preparation could improve this. Conversely, other highly ranked platforms, *ePlex System* (Roche Diagnostics, Switzerland) and *Idylla™*, though not requiring sample pre-treatment, need continuous power and only operate at temperatures up to 30 °C, with longer turnaround times (90 to 120 minutes) for 3 to 8 samples. Their multiplexing capacity and high throughput suit urban centers with substantial test volumes and laboratory infrastructure, similar to *GeneXpert Dx*^[26].

GENERAL FINDINGS

Overall, we observed a lack of transparency in the reporting of instrument and test costs, and where reported, they often exceeded WHO pricing recommendations. Currently, equitable access to WHO-recommended rapid molecular tests remains elusive in LMICs despite large-scale investments and price negotiations led by multiple stakeholders^[26, 49, 50]. Addressing global affordability and accessibility requires diversified diagnostic manufacturing and minimized maintenance requirements^[51]. However, most COVID-19 test manufacturers are in high-income countries, hindering global access^[51]. Translation of identified tests to TB would require commitment from these companies to global health and global access terms. SD Biosensor's (Suwon, South Korea) recent license agreement with the COVID-19 Technology Access Pool for its COVID-19 antigen test, under which nonexclusive sublicensees will receive the knowledge and materials to manufacture the technology could serve as a model for TB diagnostics^[52]. Lastly, many identified tests lack independently reported clinical performance estimates, or discrepancies between developer- and

independently reported values exist. This is in line with recent findings on overestimated developer-reported sensitivity estimates of rapid SARS-CoV-2 antigen tests ^[53].

This scoping review has multiple strengths. We conducted inclusive searches across various sources, including published studies, pre-prints, regulatory databases, and IVD manufacturers websites. This ensures a broad coverage of technologies from diverse developers, including start-ups, and large-scale IVD corporations. Data accuracy was ensured through rigorous screening conducted by two independent reviewers and cross-verification of charted data with developer-reported information. Lastly, objective scoring aligned with WHO TPPs was used to mitigate subjective reporting and to evaluate test characteristics of POC diagnostic devices against WHO standards.

Several limitations should be noted. First, due to the extensive dataset and time constraints, charted data were not cross-verified by a second reviewer, and early-stage non-commercialized platforms were excluded, potentially overlooking promising new technologies. Second, our search of IVD databases was confined to the openly accessible ones with English search functionality, resulting in a potential bias. Further, the scoring criteria based on *Lehe et al's* scorecard require refinement, including weighing individual scores based on their relative importance to end-users in peripheral settings, and including additional TPP parameters. Also, the chosen scoring criteria were not specifically tailored to the various technology classes and test classifications. Some criteria are more applicable to certain technology classes than others. Lastly, data limitations, such as untransparent cost reporting and lack of clinical and analytical performance data may introduce bias in device scoring.

5 CONCLUSIONS

This scoping review has highlighted the potential for adapting SARS-CoV-2 POC diagnostic technologies for TB diagnosis, identifying 58 commercially available molecular and antigen tests that may meet WHO TPPs for peripheral settings. Despite the promising potential of several platforms, challenges remain, such as the need for optimized sample pre-treatment and considerations for deployment in resource-limited settings with varying environmental conditions. Additionally, addressing affordability and accessibility through diversified manufacturing and global health commitments is essential. Pricing structures must reflect the value across diverse settings, justifying costs with benefits like increased decentralization and enhanced clinical utility. Context-adapted diagnostic tests that integrate into local TB diagnostic algorithms and policies are preferred over one-size-fits-all solutions. This review serves as a foundational step toward leveraging COVID-19 diagnostic innovations to bridge the TB diagnostic gap, urging stakeholders to foster collaborations that translate these findings into impactful TB diagnostic solutions.

6 STATEMENTS AND DECLARATIONS

Ethics and Dissemination

This scoping review did not require ethical approval because it does not involve individual patient data and uses sources that are in the public domain.

Patient and Public Involvement

No patients were involved in the study's design, planning, or conception.

Funding Statement

This systematic review is funded by the National Institutes of Health (NIH) (funding reference number U01AI152087; Rapid Research in Diagnostics Development for Tuberculosis Network).

Author's Contributions

S.Y. developed the scoping review protocol. L.H. and S.Y. collected, screened, and extracted data. L.H., S.Y., S.J. and R.D. reviewed and analyzed the data. L.H. S.Y. and S.J. drafted the manuscript. All co-authors provided critical editing and review. The final version was approved by all co-authors prior to publication.

Author's contact

Lydia Holtgrewe (Corresponding author): lmlh1g18@soton.ac.uk, Heidelberg University Hospital, Division of Infectious Diseases and Tropical Medicine, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany, +49(0) 6221- 56-35091

Lydia Holtgrewe: lmlh1g18@soton.ac.uk

Sonal Jain: sonal.jain@uni-heidelberg.de

Ralitza Dekova: Ralitza.dekova@uni-heidelberg.de

Tobias Broger: tobias.broger@uni-heidelberg.de

Chris Isaacs: chris.isaacs@connected-dx.com

Payam Nahid: pnahid@ucsf.edu

Adithya Cattamanchi: Adithya.Cattamanchi@ucsf.edu

Claudia Denking: Claudia.Denking@uni-heidelberg.de

Seda Yerlikaya: seda.yerlikaya@uni-heidelberg.de

Competing Interest Statement

Authors declare no financial conflict of interest. T.B. holds patents in the fields of lipoarabinomannan detection and aerosol collection, and is a shareholder of Avelo Ltd, a Swiss diagnostic company. C.I. is the founder and director of Connected Diagnostics Limited, a UK-based commercial entity that assists companies with the development of diagnostic devices. C.D. is a member of the Scientific Advisory Committee of Avelo Ltd.

Acknowledgments

The abstract was partially generated by ChatGPT (powered by OpenAI's language model, GPT-3.5; <http://openai.com>). The editing was performed by the human authors.

7 REFERENCES

1. PAHO. *Tuberculosis response recovering from pandemic but accelerated efforts needed to meet new targets*. 2023 [cited 2023 Jan 08]; Available from: [https://www.paho.org/en/news/7-11-2023-tuberculosis-response-recovering-pandemic-accelerated-efforts-needed-meet-new#:~:text=7%20November%202023%20\(PAHO\)%2D,19%20disruptions%20on%20TB%20services](https://www.paho.org/en/news/7-11-2023-tuberculosis-response-recovering-pandemic-accelerated-efforts-needed-meet-new#:~:text=7%20November%202023%20(PAHO)%2D,19%20disruptions%20on%20TB%20services).
2. Sachdeva, K.S. and N. Kumar, *Closing the gaps in tuberculosis detection-considerations for policy makers*. Lancet Glob Health, 2023. **11**(2): p. e185-e186.
3. Subbaraman, R., T. Jhaveri, and R.R. Nathavitharana, *Closing gaps in the tuberculosis care cascade: an action-oriented research agenda*. J Clin Tuberc Other Mycobact Dis, 2020. **19**: p. 100144.
4. WHO, *WHO High-priority target product profiles for new tuberculosis diagnostics*. 2014.
5. Nandlal, L., R. Perumal, and K. Naidoo, *Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis*. Infect Drug Resist, 2022. **15**: p. 4971-4984.
6. Yerlikaya, S., et al., *Blazing the trail for innovative tuberculosis diagnostics*. Infection, 2023.
7. Chopra, K.K. and S. Singh, *Tuberculosis: Newer diagnostic tests: Applications and limitations*. Indian J Tuberc, 2020. **67**(4S): p. S86-S90.
8. WHO, *WHO standard: universal access to rapid tuberculosis diagnostics*. 2023.
9. Ismail, N., et al., *Achieving universal access to rapid tuberculosis diagnostics*. BMJ Glob Health, 2023. **8**(5).
10. WHO, *Global Tuberculosis Report*. 2023.
11. Research, T.M., <https://www.who.int/publications/i/item/9789240083851>. 2023.

12. Research, G.V., *COVID-19 Diagnostics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Reagents & Kits, Services), By Sample Type, By Test Type, By Mode, By End Use, By Region, And Segment Forecasts, 2022 - 2030*. 2024.
13. Levac, D., H. Colquhoun, and K.K. O'Brien, *Scoping studies: advancing the methodology*. Implement Sci, 2010. **5**: p. 69.
14. Tricco, A.C., et al., *PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation*. Ann Intern Med, 2018. **169**(7): p. 467-473.
15. Yerlikaya, S., et al., *Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol*. BMJ Open, 2023. **13**(2): p. e065194.
16. Commission, E. *EUDAMED - European Database on Medical Devices*. 2021 [cited 2023 Dec 07, 2023]; Available from: <https://ec.europa.eu/tools/eudamed/#/screen/home>.
17. Innovation, V.H. *Covidence [Computer software]*. 2024 [cited 2024 Apr 4]; Available from: <https://support.covidence.org/help/how-can-i-cite-covidence>Melourne,.
18. Lehe, J.D., et al., *Evaluating operational specifications of point-of-care diagnostic tests: a standardized scorecard*. PLoS One, 2012. **7**(10): p. e47459.
19. 360Dx. *Roche to Acquire LumiraDx Point-of-Care Testing Tech for up to \$350M*. 2024 [cited 2024 Apr 5]; Available from: https://www.360dx.com/business-news/roche-acquire-lumiradx-point-care-testing-tech-350m?CSAuthResp=1712329219737%3A0%3A2731195%3A1911%3A24%3Asuccess%3AF7A508B010CAA6F6BDBA33CDA751578C&_ga=2.119195471.790131286.1712329165-1006766003.1711110768&adobe_mc=MC MID%3D26734529761092225790874085618419779486%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1712329173.
20. Kruger, L.J., et al., *Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx: An antigen-detecting point-of-care device for SARS-CoV-2*. Infection, 2022. **50**(2): p. 395-406.
21. Broger, T., et al., *Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients*. J Clin Invest, 2020. **130**(11): p. 5756-5764.
22. Arnaout, R., et al., *SARS-CoV2 Testing: The Limit of Detection Matters*. bioRxiv, 2020.
23. Broger, T., et al., *Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients*. PloS one, 2019. **14**(4): p. e0215443-NA.
24. Bulterys, M.A., et al., *Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update*. Journal of clinical medicine, 2019. **9**(1): p. 111-NA.

25. Twabi, H.H., *TB Diagnostics: Existing Platform and Future Direction*. Am J Biomed Sci & Res, 2022. **2022 - 15(6)**.
26. Pai, M., P.K. Dewan, and S. Swaminathan, *Transforming tuberculosis diagnosis*. Nat Microbiol, 2023. **8(5)**: p. 756-759.
27. Luabeya, A.K., et al., *Noninvasive Detection of Tuberculosis by Oral Swab Analysis*. J Clin Microbiol, 2019. **57(3)**.
28. Molina-Moya, B., et al., *Molecular Detection of Mycobacterium tuberculosis in Oral Mucosa from Patients with Presumptive Tuberculosis*. J Clin Med, 2020. **9(12)**.
29. Steadman, A., et al., *New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics*. Clin Infect Dis, 2024.
30. Williams, C.M., et al., *Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies*. Lancet Infect Dis, 2020. **20(5)**: p. 607-617.
31. Williams, C.M., et al., *Face mask sampling for the detection of Mycobacterium tuberculosis in expelled aerosols*. PLoS One, 2014. **9(8)**: p. e104921.
32. Mafirakureva, N., et al., *Xpert Ultra stool testing to diagnose tuberculosis in children in Ethiopia and Indonesia: a model-based cost-effectiveness analysis*. BMJ Open, 2022. **12(7)**: p. e058388.
33. Dubale, M., et al., *Stool-based Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children at a teaching and referral hospital in Southwest Ethiopia*. PLoS One, 2022. **17(5)**: p. e0267661.
34. Mesman, A.W., et al., *Diagnostic accuracy of molecular detection of Mycobacterium tuberculosis in pediatric stool samples: A systematic review and meta-analysis*. Tuberculosis (Edinb), 2019. **119**: p. 101878.
35. Aiano, F., et al., *Feasibility and acceptability of SARS-CoV-2 testing and surveillance in primary school children in England: Prospective, cross-sectional study*. PLoS One, 2021. **16(8)**: p. e0255517.
36. Daniels, B., et al., *Lessons on the quality of tuberculosis diagnosis from standardized patients in China, India, Kenya, and South Africa*. J Clin Tuberc Other Mycobact Dis, 2019. **16**: p. 100109.
37. Ferguson, T.M., et al., *Pilot study of a rapid and minimally instrumented sputum sample preparation method for molecular diagnosis of tuberculosis*. Sci Rep, 2016. **6**: p. 19541.
38. Vandeventer, P.E., et al., *Mechanical disruption of lysis-resistant bacterial cells by use of a miniature, low-power, disposable device*. J Clin Microbiol, 2011. **49(7)**: p. 2533-9.

39. Jaroenram, W., et al., *Ultrasensitive detection of Mycobacterium tuberculosis by a rapid and specific probe-triggered one-step, simultaneous DNA hybridization and isothermal amplification combined with a lateral flow dipstick*. Sci Rep, 2020. **10**(1): p. 16976.
40. Shanmugakani, R.K., et al., *An isothermal amplification-based point-of-care diagnostic platform for the detection of Mycobacterium tuberculosis: A proof-of-concept study*. Curr Res Biotechnol, 2021. **3**: p. 154-159.
41. Denking, C.M., et al., *Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?* Eur Respir J, 2013. **42**(2): p. 544-7.
42. Andre, E., et al., *Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination*. Int J Tuberc Lung Dis, 2016. **20**(8): p. 999-1003.
43. Albert, H., et al., *Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?* Eur Respir J, 2016. **48**(2): p. 516-25.
44. Dowell, D., et al., *Integration of Surveillance for STDs, HIV, Hepatitis, and TB: A Survey of U.S. STD Control Programs*. Public Health Rep, 2009. **124 Suppl 2**(Suppl 2): p. 31-8.
45. Organization, W.H. *WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters*. 2023 Oct 19, 2023 [cited 2024 Mar 14, 2024]; Available from: <https://www.who.int/news/item/19-10-2023-who-releases-new-list-of-essential-diagnostics--new-recommendations-for-hepatitis-e-virus-tests--personal-use-glucose-meters>.
46. Trang, B. *Cue Health, Covid-19 testing company, is shutting down*. 2024 [cited 2024 Jun 11, 2024]; Available from: <https://www.statnews.com/2024/05/22/cue-health-covid-19-test-maker-layoffs/#:~:text=In%20an%20abrupt%20change,as%20of%20Friday%2C%20May%2024>.
47. Organization, W.H., *WHO consolidated guidelines on tuberculosis: Module 3: diagnosis – rapid diagnostics for tuberculosis detection*. 2021, WHO: Geneva.
48. OptiGene. *LAMP Designer*. 2024 [cited 2024 Mar 14, 2024]; Available from: <https://www.optigene.co.uk/lamp-designer/>.
49. Ntinginya, N.E., et al., *Unlocking the health system barriers to maximise the uptake and utilisation of molecular diagnostics in low-income and middle-income country setting*. BMJ Glob Health, 2021. **6**(8).
50. FIND. *Accessible pricing*. 2024 [cited 2024 Mar 15, 2024]; Available from: <https://www.finddx.org/what-we-do/cross-cutting-workstreams/market-innovations/accessible-pricing/>.
51. Hannay, E. and M. Pai, *Breaking the cycle of neglect: building on momentum from COVID-19 to drive access to diagnostic testing*. EClinicalMedicine, 2023. **57**: p. 101867.

52. 360Dx. *WHO, Medicines Patent Pool License Rapid Diagnostics Technology From SD Biosensor*. 2024 [cited Mar 22 2024]; Available from: https://www.360dx.com/business-news/who-medicines-patent-pool-license-rapid-diagnostics-technology-sd-biosensor?adobe_mc=MCMID%3D19782619068757078863840638341405804837%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1706883764&CSAuthResp=1%3A%3A2548842%3A273%3A24%3Asuccess%3A33042812B2DBBA2FDB7574A1C2C8E150.
53. Bigio, J., et al., *Accuracy of package inserts of SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus systematic review data*. *Lancet Microbe*, 2023. **4**(11): p. e875-e882.